Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvolvE: Barzolvolimab in Adults with Active Eosinophilic Esophagitis
2022-001786-12Phase 2Active
- Sponsor
- Celldex Therapeutics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Barzolvolimab with Placebo (2 arms). Primary endpoint: Absolute change from baseline to Week 12 in peak esophageal intraepithelial mast cell count per high power field. Started Dec 2022; status: active.
02
Drugs
barzolvolimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2022-001786-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001786-12.